Request Demo
Recent blog posts
Latest Hotspot
8 min read
Navepegritide Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
20 July 2026
Navepegritide: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Nitroxoline Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
20 July 2026
Nitroxoline: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Vornorexant Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
20 July 2026
Vornorexant: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Felbinac Trometamol Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
20 July 2026
Felbinac Trometamol: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Paltusotine Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
20 July 2026
Paltusotine: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Rovadicitinib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
20 July 2026
Rovadicitinib: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Tradipitant Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
20 July 2026
Tradipitant: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Estetrol Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
20 July 2026
Estetrol: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Elamipretide Hydrochloride Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
20 July 2026
Elamipretide Hydrochloride: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Zeprumetostat Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
20 July 2026
Zeprumetostat: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Anagliptin/Empagliflozin Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
20 July 2026
Anagliptin/Empagliflozin: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Retlirafusp alfa Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
20 July 2026
Retlirafusp alfa: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.